Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Harbor BioSciences granted US patent for Triolex metabolic disease and anti-inflammation drug candidate

Harbor BioSciences, Inc. today announced that the company has received patent No. 7,776,845 from the United States Patent and Trademark Office which covers its lead metabolic disease and anti-inflammation drug candidate Triolex (HE3286). The patent claims cover compounds including Triolex and formulations that contain the drug or the other claimed compounds.

20 Sep 2010

Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients

Bristol-Myers Squibb Company and AstraZeneca today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in glycosylated hemoglobin levels (HbA1c) in adult patients with type 2 diabetes compared to glimepiride alone.

20 Sep 2010

Sanofi-aventis releases Lantus(R) study results for type 2 diabetes

Sanofi-aventis announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.

20 Sep 2010

Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD

Sanofi-aventis announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.

20 Sep 2010

Lisofylline drug effective for Type 2 diabetes

Australian scientists, in association with US pharmaceutical company DiaKine Therapeutics, have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes.

20 Sep 2010

New law brings changes to health insurance rules this week

A variety of consumer friendly health reform rules will go into effect this week, promising to make life easier for young adults, parents, children with preexisting conditions, people with chronic diseases, and people appealing claims that have been denied. Starting Thursday, insurance companies must allow young adults to remain on their parents' plans until age 26, with some conditions.

20 Sep 2010

Improper biological clocks tend to develop diabetes, obesity: Research

Biologists have found that a key protein that regulates the biological clocks of mammals also regulates glucose production in the liver and that altering the levels of this protein can improve the health of diabetic mice.

20 Sep 2010

POWER study: Women with diabetes have C-section, complications during pregnancy

Nearly half of women with diabetes prior to pregnancy have a potentially-avoidable C-section and their babies are twice as likely to die as those born to women without diabetes, according to the POWER study.

18 Sep 2010

Atherotech Diagnostics publishes article on advantages of cholesterol testing

Detailed cholesterol testing for Type 2 diabetes patients is the focus of a newly published article by Atherotech Diagnostics Lab Chief Medical Officer Michael E. Cobble, M.D. The article discusses the clinical advantages of advanced cholesterol testing in reducing cardiovascular disease (CVD) risk in patients with Type 2 diabetes and details several currently available advanced lipid tests, including the VAP® Cholesterol Test from Atherotech.

18 Sep 2010

Use of oral medications for diabetes increases among Americans: Report

The proportion of Americans reporting treatment for diabetes who took oral medications to treat their condition increased from 60 percent in 1997 to 77 percent in 2007, a 28 percent increase according to the latest News and Numbers from the Agency for Healthcare Research and Quality. During the same period, the proportion taking insulin to control their diabetes fell from 38 percent to 24 percent.

18 Sep 2010

FDA reviews Actos drug for bladder cancer risk

The U.S. Food and Drug Administration today announced it has begun a safety review of the diabetes drug Actos (pioglitazone), after receiving preliminary results from a long-term observational study designed to evaluate the risk of bladder cancer associated with use of this drug.

18 Sep 2010

Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes

Transition Therapeutics Inc. announced today that a clinical study of gastrin analogue TT-223 in combination with a Lilly proprietary GLP-1 analogue in patients with type 2 diabetes did not meet its efficacy endpoints. Given these findings, there will be no further development of TT-223.

17 Sep 2010

Blood vessel growth promoting microRNA predicts diabetes: Study

For the first time, scientists have found that blood levels of some ribonucleic acids (microRNAs) are different among people with type 2 diabetes and those who subsequently develop the disease compared to healthy controls, according to research reported in Circulation Research: Journal of the American Heart Association.

17 Sep 2010

Researchers find bariatric surgery reduces cardiovascular disease risk

Significant weight loss not only improves daily life of morbidly obese woman but also decreases the risk for cardiovascular disease (CVD). However, many people can not lose weight or can not maintain weight loss without help. Bariatric surgery is emerging as a valuable procedure to help morbidly obese individuals lose weight, as studies have shown; it can improve many health profiles and lower mortality. Now, researchers have found another positive impact of significant weight loss after bariatric surgery, it can significantly improve the lipoprotein profiles of women within a year following surgery.

17 Sep 2010

Metabolic Solutions to present MSDC-0160 clinical candidate data at EASD conference

Metabolic Solutions Development Company (MSDC), will present research at the European Association for the Study of Diabetes (EASD) annual conference in Stockholm, Sweden on Sept. 23, 2010. The research indicates that the company's clinical candidate, MSDC-0160, promotes the proliferation of stem cells that create brown fat, leading to the creation of more brown fat. The research was conducted in tissue cultures and mice.

17 Sep 2010

Survey reveals 72% of people over age of 65 do not feel old

There is a sharp contrast between people's positive attitudes towards growing old and their preparedness according to the results of a new international survey, Bupa Health Pulse 2010, published today by Bupa Health Dialog.

17 Sep 2010

Community diabetes self-management education program helps Latinos with type 2 diabetes: Study

A diabetes self-management education program delivered by community health workers may be effective in improving the blood sugar levels and behavioral skills among Hispanics/Latinos with type 2 diabetes, according to a recent University of Illinois at Chicago study.

16 Sep 2010

BCBC Consortium aims to develop cell-based therapy for insulin delivery

Oregon Health & Science University's Markus Grompe, M.D., will lead a multi-center team of scientists selected to participate in the prestigious Beta Cell Biology Consortium (BCBC). Funded by the National Institute of Diabetes and Digestive and Kidney Diseases, the consortium's long-term goal is to develop a cell-based therapy for insulin delivery in type 1 diabetes patients.

16 Sep 2010

Jaeb Center for Health Research awarded $26M grant to accelerate new therapies for type 1 diabetes

The Leona M. and Harry B. Helmsley Charitable Trust, a leader in type 1 diabetes research funding, today announced that the Trust has awarded a three-year, $26 million grant to the Jaeb Center for Health Research. The grant is for the development of a type 1 diabetes exchange that includes a data repository, a biobank and an interactive website with mobile capability.

16 Sep 2010

Oramed Pharmaceuticals announces clinical trial results of ORMD-0801 capsule in Type I diabetics

Oramed Pharmaceuticals Inc. announced today successful results in an exploratory clinical trial testing the effectiveness of its oral insulin capsule (ORMD-0801) in Type I diabetes patients suffering from uncontrolled diabetes.

15 Sep 2010

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Harbor BioSciences granted US patent for Triolex metabolic disease and anti-inflammation drug candidate

Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients

Sanofi-aventis releases Lantus(R) study results for type 2 diabetes

Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD

Lisofylline drug effective for Type 2 diabetes

New law brings changes to health insurance rules this week

Improper biological clocks tend to develop diabetes, obesity: Research

POWER study: Women with diabetes have C-section, complications during pregnancy

Atherotech Diagnostics publishes article on advantages of cholesterol testing

Use of oral medications for diabetes increases among Americans: Report

FDA reviews Actos drug for bladder cancer risk

Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes

Blood vessel growth promoting microRNA predicts diabetes: Study

Researchers find bariatric surgery reduces cardiovascular disease risk

Metabolic Solutions to present MSDC-0160 clinical candidate data at EASD conference

Survey reveals 72% of people over age of 65 do not feel old

Community diabetes self-management education program helps Latinos with type 2 diabetes: Study

BCBC Consortium aims to develop cell-based therapy for insulin delivery

Jaeb Center for Health Research awarded $26M grant to accelerate new therapies for type 1 diabetes

Oramed Pharmaceuticals announces clinical trial results of ORMD-0801 capsule in Type I diabetics

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in